Form 4: Oric Pharmaceuticals Chief Medical Officer Acquires Stock Options and Restricted Stock Units

Pratik S. Multani, Chief Medical Officer of Oric Pharmaceuticals, acquired stock options for 202,500 shares and 34,000 restricted stock units on January 2, 2025.

Summary

• Pratik S. Multani, the Chief Medical Officer of Oric Pharmaceuticals, filed a Form 4 on January 3, 2025.
• The filing reports the acquisition of stock options and restricted stock units (RSUs).
• Multani acquired options for 202,500 shares of common stock at an exercise price of $8.26 on January 2, 2025.
• These options vest over time, with 25% vesting on January 2, 2026, and the remainder vesting monthly thereafter.
• Multani also acquired 34,000 RSUs, each representing a contingent right to receive one share of Oric Pharmaceuticals common stock.
• These RSUs vest in three equal installments on December 15, 2025, December 15, 2026, and December 15, 2027.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options and RSUs to a key executive suggests confidence in the company's future, but it's a routine event.

Positives

• The acquisition of stock options and RSUs by a key executive like the Chief Medical Officer can be seen as a positive sign, indicating confidence in the company's future performance.
• The vesting schedules for both the options and RSUs incentivize the executive to remain with the company and contribute to its long-term success.

Future Outlook

The document does not contain specific forward-looking statements about the company's overall future outlook, but the vesting schedules suggest a multi-year commitment from the executive.

Industry Context

Stock options and RSUs are common forms of executive compensation in the pharmaceutical industry, used to align management's interests with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry, often used by companies like Amgen, Gilead Sciences, and Regeneron.
• The vesting schedule of the options (25% after one year, then monthly) is fairly typical, aligning with industry norms for incentivizing long-term performance.
• RSUs are also a common tool, with vesting schedules often tied to specific performance milestones or continued employment, similar to practices at companies like Vertex Pharmaceuticals and Biogen.

Stakeholder Impact

• Shareholders may view the granting of stock options and RSUs as a positive sign, aligning management's interests with theirs.
• Employees may see this as a sign of the company's commitment to its leadership team.

Key Dates